Objective: This study aims to study and discuss the promotion of microRNA-214 hypoxia-induced Pulmonary Hypertension (PH) in patients with molecular mechanisms of pulmonary artery smooth muscle cell proliferation, to provide a theoretical basis for clinical prevention and treatment of PH.
Methods: From January 2011 to December 2014 in our hospital for treatment of patients with Chronic Obstructive Pulmonary Disease (COPD) combined PH of 15 and 15 patients with COPD alone. All patients because associated with lung cancer underwent lobectomy, isolated and cultured Pulmonary Arterial Smooth Muscle Cells (PASMCs). In this study, luciferase assay techniques to determine the molecular targets of miR-214, and by RT-PCR and Western blot to detect the expression.
Results: Luciferase assay technique shows miR-214 target molecules as cyclin L2 (CCNL2). CCNL2 expression of COPD patients with PH combined PASMCs significantly lower than that in patients with COPD.
Conclusion: MicroRNA-214 downregulates the cyclin L2 in pulmonary artery smooth muscle cells.